---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-011560"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2023-04-07T23:59:59+00:00"
generated_at: "2026-06-17T04:50:25.899137+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech funds immune monitoring study & hires consultant for pancreatic cancer Ampligen trial

## Summary
- Entered $200K grant with Erasmus MC for immune monitoring in pancreatic cancer patients.
- Hired Dr. Casper H.J. van Eijck as consultant to recruit European sites for Ampligen pancreatic cancer trials.
- Consultant to also introduce COVID, Long COVID & pancreatic cancer studies into Poland.
- Consulting fee: up to $2,000/month; aggregate cap of $24,500 after AMP-270 study start.

## SEC filing metadata
- accession: 0001493152-23-011560
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2023-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315223011560/0001493152-23-011560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315223011560/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-011560
- JSON: https://secwatch.observer/filing/0001493152-23-011560.json
- Plain text: https://secwatch.observer/filing/0001493152-23-011560.txt

## Key facts
- Material Agreements
  AIM ImmunoTech Inc. entered into Unrestricted Grant Agreement with Erasmus University Medical Center (effective 2023-04-04).
  - Action: entry
  - Counterparty: Erasmus University Medical Center
  - Effective: 2023-04-04
  source text: On April 4, 2023, AIM ImmunoTech Inc. (the “Company”) executed an Unrestricted Grant Agreement with Erasmus University Medical Center (“EUMC”) pursuant to which EUMC will use its best efforts to diligently carry out immune monitoring in pancreatic cancer patients.
  evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315223011560/0001493152-23-011560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.